Abstract
BackgroundRheumatologic, dermatologic and inflammatory bowel disorders (IBD) can affect women of childbearing potential. Infliximab ([IFX], Innovator) is approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
